Caladrius Biosciences, Inc. (CLBS)
| Market Cap | 122.58M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -7.68M |
| Shares Out | 18.60M |
| EPS (ttm) | -0.58 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 25 |
| Last Price | $2.02 |
| Previous Close | $2.12 |
| Change ($) | -0.11 |
| Change (%) | -4.95% |
| Day's Open | 2.08 |
| Day's Range | 1.93 - 2.10 |
| Day's Volume | 2,931,472 |
| 52-Week Range | 1.05 - 4.89 |
BASKING RIDGE, N.J., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the de...
BASKING RIDGE, N.J., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the de...
BASKING RIDGE, N.J., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the de...
BASKING RIDGE, N.J., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the de...
BASKING RIDGE, N.J., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the de...
BASKING RIDGE, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the de...
Caladrius Biosciences is focused on treating coronary microvascular dysfunction. The condition is most common among women, especially after menopause.
Initiation of the Phase 2b FREEDOM trial represents the next step in development of CLBS16 as a potential breakthrough treatment for the millions of sufferers of CMD in the U.S., most of whom ...
BASKING RIDGE, N.J., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the de...
The short term investor may want to consider this trio of companies
BASKING RIDGE, N.J., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the de...
The Company retains Robert Honigberg, M.D., as interim Chief Medical Officer The Company retains Robert Honigberg, M.D., as interim Chief Medical Officer
BASKING RIDGE, N.J., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the de...
Caladrius Biosciences' (CLBS) CEO David Mazzo on Q3 2020 Results - Earnings Call Transcript
BASKING RIDGE, N.J. , Nov. 04, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the d...
BASKING RIDGE, N.J., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the de...
BASKING RIDGE, N.J., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the de...
BASKING RIDGE, N.J., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the de...
Patient screening begins immediately at NYU Langone Health
BASKING RIDGE, N.J., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the de...
BASKING RIDGE, N.J., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the de...
BASKING RIDGE, N.J., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
Caladrius Biosciences to Present at H.C. Wainwright 22nd Annual Global Investment Virtual Conference
BASKING RIDGE, N.J., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
Caladrius Biosciences' (CLBS) CEO David Mazzo on Q2 2020 Results - Earnings Call Transcript
BASKING RIDGE, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the ...
BASKING RIDGE, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the ...
BASKING RIDGE, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the ...
Investors need to pay close attention to Caladrius Biosciences (CLBS) stock based on the movements in the options market lately.
BASKING RIDGE, N.J., May 28, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the d...
Single administration of CLBS16 durably improves heart function and symptoms in patients with coronary microvascular dysfunction Single administration of CLBS16 durably improves heart function...
Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q1 2020 Results - Earnings Call Transcript
BASKING RIDGE, N.J., April 27, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
BASKING RIDGE, N.J., April 23, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
FDA authorizes new IND for the study of CLBS119 in COVID-19 patients who experienced respiratory failure FDA authorizes new IND for the study of CLBS119 in COVID-19 patients who experienced re...
BASKING RIDGE, N.J., April 22, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), today announced that it has finalized an agreement to sell ...
Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q4 2019 Results - Earnings Call Transcript
Single administration of CLBS16 durably improves heart function and symptoms with no cell-related adverse events
Caladrius Biosciences' (CLBS) CEO David Mazzo on Q3 2019 Results - Earnings Call Transcript
Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q2 2019 Results - Earnings Call Transcript
Top Ranked Momentum Stocks to Buy for July 25th
Caladrius Biosciences, Inc.'s (CLBS) CEO David Mazzo on Q1 2019 Earnings Conference Call Transcript
Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q4 2018 Earnings Conference Call Transcript
About CLBS
Caladrius Biosciences, a clinical-stage biopharmaceutical company, develops cellular therapeutic product candidates to address diseases and conditions caused by ischemia. Its product candidates include developmental treatments for cardiovascular diseases, such as CLBS12 for the treatment of critical limb ischemia; CLBS16, which is in Phase II clinical trial for the treatment of coronary microvascular dysfunction; CLBS14, a regenerative medicine advanced therapy for treating no-option refractory disabling angina. The company was formerly known a... [Read more...]
| Industry Biotechnology | Founded 1980 |
| CEO David Mazzo | Employees 27 |
| Stock Exchange NASDAQ | Ticker Symbol CLBS |
Analyst Forecasts
According to 2 analysts, the average rating for CLBS stock is "Buy." The 12-month stock price forecast is 9.00, which is an increase of 346.65% from the latest price.